Wealth Alliance Raises Position in Repligen Co. (NASDAQ:RGEN)

Wealth Alliance lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 16.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,941 shares of the biotechnology company’s stock after acquiring an additional 277 shares during the quarter. Wealth Alliance’s holdings in Repligen were worth $349,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its stake in shares of Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock worth $1,663,000 after buying an additional 159 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after acquiring an additional 58,299 shares during the period. American Century Companies Inc. boosted its position in shares of Repligen by 97.5% during the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock worth $34,648,000 after purchasing an additional 107,570 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Repligen during the 4th quarter worth $2,625,000. Finally, Atria Investments Inc purchased a new position in shares of Repligen in the 3rd quarter valued at about $1,046,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 2.4 %

Shares of NASDAQ:RGEN opened at $157.06 on Friday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $8.77 billion, a P/E ratio of 218.14, a P/E/G ratio of 5.27 and a beta of 1.02. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The stock’s fifty day simple moving average is $190.02 and its 200-day simple moving average is $173.20.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.68 EPS. As a group, equities research analysts forecast that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RGEN. Stifel Nicolaus boosted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp upped their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Insider Buying and Selling

In other Repligen news, COO James Bylund sold 4,373 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Repligen news, COO James Bylund sold 4,373 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.